



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau9902780-7
IPAS copy

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 409/04, A61K 31/47, 31/505, C07D 405/04, 401/04, 471/04, 401/14, 413/04 // (C07D 471/04, 221:00, 221:00) (C07D 471/04, 239:00, 221:00)	A1	(11) International Publication Number: WO 98/30560 (43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/EP98/00143 (22) International Filing Date: 6 January 1998 (06.01.98) (30) Priority Data: 9700504.5 ✓ 11 January 1997 (11.01.97) ✓ GB (71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (71) Applicant (for all designated States except GB US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): FOX, David, Nathan; Abraham [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, European Patent Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA ✓



(57) Abstract

Compounds of formula (I), wherein R¹ represents C₁₋₄ alkoxy optionally substituted by one or more fluorine atoms; R² represents H or C₁₋₆ alkoxy optionally substituted by one or more fluorine atoms; R³ represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted; R⁴ represents a 4-, 5-, 6- or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent, or represents a cyclic group of formula (Ia), or represents a chain of formula (Ib), and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.